BioCentury | Dec 20, 2019
Clinical News

Stealth cites endpoints in Phase III mitochondrial disease miss

...Shares of Stealth BioTherapeutics sank 65% to $4.75 on Friday after the company announced a Phase III...
...Total Fatigue Scores in the Phase III MMPOWER-3 trial. During an investor call on Monday, Stealth BioTherapeutics Corp....
...Story Hits $930M High Note” ). Lauren Martz, Associate Editor Subcutaneous elamipretide (MTP-131, bendavia, ocuvia, ss-31) Alexion Pharmaceuticals Inc. Stealth BioTherapeutics Corp....
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...spent over $100 million in upfront payments across four partnerships, the most recent being with Stealth BioTherapeutics Corp....
BioCentury | Oct 11, 2019
Company News

Alexion deal lends late-stage support to Stealth

...is expected in January. Stealth said an NDA submission to FDA is tentative for 3Q20. Stealth BioTherapeutics Corp....
...to speeding up and improving medical research. Elizabeth S. Eaton, Staff Writer Subcutaneous elamipretide (MTP-131, bendavia, ocuvia, ss-31) Stealth BioTherapeutics Corp. Alexion...
BioCentury | Sep 4, 2019
Company News

Management tracks: PhRMA, Arcus, Beam, Stealth, Bolt, Athenex, Click, Melinta, Kallyope and Genor

...a managing director in the healthcare investment banking group at J.P. Morgan. Mitochondrial disease company Stealth BioTherapeutics Corp....
...Biotherapeutics Inc. Click Therapeutics Inc. Genor Biopharma Co. Ltd. Kallyope Inc. Melinta Therapeutics Inc. Pharmaceutical Research and Manufacturers of America (PhRMA) Stealth BioTherapeutics...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...KOSDAQ:299660) 2/20/19 $35.2 $276.8 $239.6 -13% Hoth Therapeutics Inc. (NASDAQ:HOTH) 2/15/19 $7.0 $52.8 $55.8 6% Stealth BioTherapeutics Corp....
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...III data Mid-2019 Sol-Gel Technologies Ltd. (NASDAQ:SLGL) TWIN (S6G5T) Treat acne Phase III data 4Q19 Stealth BioTherapeutics Corp....
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

...identified two other companies with late-stage therapies for FAOD and PMM: Ultragenyx Pharmaceutical Inc. and Stealth BioTherapeutics Corp....
...San Rafael, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Reneo Pharmaceuticals Inc., San Diego, Calif. Stealth BioTherapeutics Corp....
BioCentury | Feb 15, 2019
Financial News

Stealth Bio prices $78M IPO at bottom end of range

...can weather the current geopolitical and macroeconomic headwinds (see "HKEX: Where East Meets West" ). Paul Bonanos Stealth BioTherapeutics...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...1/4/19 Up to $115M Ph I MicuRx Pharmaceuticals Inc. (HKEX) (A) 12/31/18 TBD Ph III Stealth BioTherapeutics Corp....
BioCentury | Jan 4, 2019
Financial News

Months after Hong Kong proposal, Stealth now seeking NASDAQ listing

..."Hong Kong's First Wave" ). Stealth BioTherapeutics Corp., Newton, Mass. Paul Bonanos elamipretide ophthalmic solution 1% (MTP-131, bendavia, ocuvia, ss-31) Stealth BioTherapeutics Corp....
Items per page:
1 - 10 of 46
BioCentury | Dec 20, 2019
Clinical News

Stealth cites endpoints in Phase III mitochondrial disease miss

...Shares of Stealth BioTherapeutics sank 65% to $4.75 on Friday after the company announced a Phase III...
...Total Fatigue Scores in the Phase III MMPOWER-3 trial. During an investor call on Monday, Stealth BioTherapeutics Corp....
...Story Hits $930M High Note” ). Lauren Martz, Associate Editor Subcutaneous elamipretide (MTP-131, bendavia, ocuvia, ss-31) Alexion Pharmaceuticals Inc. Stealth BioTherapeutics Corp....
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...spent over $100 million in upfront payments across four partnerships, the most recent being with Stealth BioTherapeutics Corp....
BioCentury | Oct 11, 2019
Company News

Alexion deal lends late-stage support to Stealth

...is expected in January. Stealth said an NDA submission to FDA is tentative for 3Q20. Stealth BioTherapeutics Corp....
...to speeding up and improving medical research. Elizabeth S. Eaton, Staff Writer Subcutaneous elamipretide (MTP-131, bendavia, ocuvia, ss-31) Stealth BioTherapeutics Corp. Alexion...
BioCentury | Sep 4, 2019
Company News

Management tracks: PhRMA, Arcus, Beam, Stealth, Bolt, Athenex, Click, Melinta, Kallyope and Genor

...a managing director in the healthcare investment banking group at J.P. Morgan. Mitochondrial disease company Stealth BioTherapeutics Corp....
...Biotherapeutics Inc. Click Therapeutics Inc. Genor Biopharma Co. Ltd. Kallyope Inc. Melinta Therapeutics Inc. Pharmaceutical Research and Manufacturers of America (PhRMA) Stealth BioTherapeutics...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...KOSDAQ:299660) 2/20/19 $35.2 $276.8 $239.6 -13% Hoth Therapeutics Inc. (NASDAQ:HOTH) 2/15/19 $7.0 $52.8 $55.8 6% Stealth BioTherapeutics Corp....
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...III data Mid-2019 Sol-Gel Technologies Ltd. (NASDAQ:SLGL) TWIN (S6G5T) Treat acne Phase III data 4Q19 Stealth BioTherapeutics Corp....
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

...identified two other companies with late-stage therapies for FAOD and PMM: Ultragenyx Pharmaceutical Inc. and Stealth BioTherapeutics Corp....
...San Rafael, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Reneo Pharmaceuticals Inc., San Diego, Calif. Stealth BioTherapeutics Corp....
BioCentury | Feb 15, 2019
Financial News

Stealth Bio prices $78M IPO at bottom end of range

...can weather the current geopolitical and macroeconomic headwinds (see "HKEX: Where East Meets West" ). Paul Bonanos Stealth BioTherapeutics...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...1/4/19 Up to $115M Ph I MicuRx Pharmaceuticals Inc. (HKEX) (A) 12/31/18 TBD Ph III Stealth BioTherapeutics Corp....
BioCentury | Jan 4, 2019
Financial News

Months after Hong Kong proposal, Stealth now seeking NASDAQ listing

..."Hong Kong's First Wave" ). Stealth BioTherapeutics Corp., Newton, Mass. Paul Bonanos elamipretide ophthalmic solution 1% (MTP-131, bendavia, ocuvia, ss-31) Stealth BioTherapeutics Corp....
Items per page:
1 - 10 of 46